Abstracts tagged "Decision Making"

Abstract Number: 0740 • ACR Convergence 2021
Rheumatologists’ and Patients’ Mental Models for Treatment of RA Explain Low Rates of TTT
Betty Hsiao¹, Julie Downs², Mandy Lanyon², William Nowell³, SHILPA VENKATACHALAM⁴, Carole Wiedmeyer⁵, Jeffrey Curtis⁶, Susan Blalock⁷, Leslie Harrold⁸ and Liana Fraenkel⁹, ¹Yale-New Haven Medical Center, New Haven, CT, ²Carnegie Mellon, Pittsburgh, PA, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, New York, NY, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁷Chapel Hill, Chapel Hill, NC, ⁸Corrona, LLC, Northborough, MA, ⁹Berkshire Medical Center, Lenox, MA
Background/Purpose: Fewer than 50% of patients with rheumatoid arthritis (RA) are treated using a TTT strategy. The purpose of this study was to better understand…
Abstract Number: 1131 • ACR Convergence 2021
Interleukin 6 Concentration in Synovial Fluid and Its Clinical Significance
Ivars Veckalns and Anna Mihailova, Riga Stradins University, Riga, Latvia
Background/Purpose: Inflammatory arthritis (IA) treated with disease modifying antirheumatic drugs lead to secondary osteoarthritis (OA) due to inflammation, aging, and other factors. Inflammatory arthritis can…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.